COMMUNIQUÉS West-GlobeNewswire
-
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
30/06/2026 -
iKrusher Invests in Canadian Operations to Improve Supply Chain Reliability and Speed to Market for Vape Brands
30/06/2026 -
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
30/06/2026 -
R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
30/06/2026 -
NurExone Announces Closing of Non-Brokered Private Placement
30/06/2026 -
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
30/06/2026 -
Commure Launches Orchestrator: The AI-Native Referral Management and Patient Intake Platform
30/06/2026 -
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
30/06/2026 -
Jushi Celebrates Enactment of Virginia Adult-Use Cannabis Legislation
30/06/2026 -
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
30/06/2026 -
Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners
30/06/2026 -
Salipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteins
30/06/2026 -
HUTCHMED to Announce 2026 Half-Year Financial Results
30/06/2026 -
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
30/06/2026 -
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
30/06/2026 -
smartbax secures additional financing to advance lead antibiotic program to IND filing
30/06/2026 -
Transactions in connection with share buy-back program
30/06/2026 -
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
30/06/2026 -
The National Proton Therapy Center of Portugal will be equipped with two IBA Proteus®ONE solutions
30/06/2026
Pages